ABSTRACT
Objective: To compare the eradication rates of H. pylori infection between a new sequential treatment regimen and conventional triple therapy in functional dyspepsia patients, and to assess the symptom improvement of functional dyspepsia. Methods: One hundred and thirty functional dyspeptic patients with H. pylori infection were randomly divided into 2 groups. Patients in sequential treatment group received 10-day sequential therapy: omeprazole (40 mg daily) plus amoxicillin (1 g twice daily) for the first 5 days, followed by omeprazole (20 mg), clarithromycin (500 mg) and tinidazole (500 mg) twice daily for the another 5 days; patients in triple therapy group received standard 7-day treatment: omeprazole (20 mg), clarithromycin (500 mg) and amoxicillin (1 g) twice daily for 7 days. H. pylori statuses were assessed by rapid urease test and 14C-urea breath test at base line level 4 weeks and one year after treatment, and symptom scores in various H. pylori statuses were evaluated. Results: The eradication rates of H. pylori in the sequential treatment group was 83.58% (56/67) by intention-to-treat(TTI) analysis and 91.80% (56/61) by per-protocol (PP) analysis, and the numbers in the triple therapy group were 65.08% (41/63) and 69.49% (41/59), respectively, which were significantly lower than those in the sequential treatment group (P<0.05). The symptom scores of patients with H. pylori eradicated after treatment were 4.88±1.76 before treatment and 2.18±0.83 one year after treatment (P<0.05); the scores of patients whose H. pylori was not eradicated after treatment was 4.99±1.66 before treatment and 3.89±1.56 one year later; there was no significant difference between the 2 numbers. Conclusion: Sequential treatment regimen has a better H. pylori eradication effect for functional dyspepsia patients positive of H. pylori than standard triple therapy; the symptom of dyspepsia can be greatly improved after H. pylori eradication.
ABSTRACT
<p><b>OBJECTIVE</b>To assess the penile erectile function, urinary continence and voiding, and cancer recurrence in 18 bladder cancer patients after sexuality preserving cystectomy and Roux-y sigmoid neobladder reconstruction.</p><p><b>METHODS</b>Eighteen male patients with bladder cancer underwent sexuality preserving cystectomy and Roux-y sigmoid neobladder reconstruction, and were followed up for cancer recurrence and such clinical outcomes as erectile function and urinary continence and voiding.</p><p><b>RESULTS</b>The patients were followed up for an average of 41 months, of whom, all achieved day- and night-time urinary continence, but 2 with positive lymph nodes died of extensive metastasis at 10 and 15 months, respectively, after surgery. Among the total number, potency was maintained in 11 patients (61.1%), impaired in 2 and lost in 5, and the post-operative IIEF-5 score was (10.83 +/- 8.25) as compared with (13.72 +/- 6.39) before the operation, with a statistically significant difference (P < 0.05).</p><p><b>CONCLUSION</b>Erectile function and urinary continence are fairly good in bladder cancer patients after sexuality preserving cystectomy and Roux-y sigmoid neobladder reconstruction, and the oncological results are fairly acceptable, but still need to be confirmed by longer follow-ups and larger trials.</p>